

5-Minute Journal Club: Defining the Future Role of TROP2-Directed Antibody-Drug Conjugates in Lung Cancer — Issue 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. In the TROPION-Lung01 study evaluating datopotamab deruxtecan (Dato-DXd) versus docetaxel for previously treated advanced or metastatic NSCLC, what was the hazard ratio for progression-free survival (PFS) in the nonsquamous cell population?
 - a. 0.41
 - b. 0.63**
 - c. 0.89
 - d. 1.15
2. In a novel assay evaluating TROP2 expression levels through a normalized membrane ratio scoring system, which of the following is true regarding efficacy in the TROPION-Lung01 study?
 - a. Lower TROP2 expression positivity appears to correlate with better PFS outcomes with Dato-DXd
 - b. Higher TROP2 expression positivity appears to correlate with better PFS outcomes with Dato-DXd**
 - c. PFS outcomes were equivocal for Dato-DXd independent of TROP2 expression levels
3. Dato-DXd recently received accelerated approval from the FDA for which indication?
 - a. Previously untreated EGFR wild-type metastatic non-small cell lung cancer (mNSCLC)
 - b. EGFR wild-type mNSCLC previously treated with platinum chemotherapy
 - c. Previously untreated EGFR-mutant mNSCLC
 - d. EGFR-mutant mNSCLC previously treated with an EGFR-directed therapy and platinum-based chemotherapy**
4. What was the objective response rate in the EGFR subpopulation in the Phase II TROPION-Lung05 study evaluating Dato-DXd for advanced or metastatic NSCLC with actionable genomic alterations progressing on or after targeted therapy and platinum-based chemotherapy?
 - a. 18%
 - b. 43%**
 - c. 71%
 - d. 100%
5. Which statement is true regarding the Phase II TROPION-Lung05 study evaluating Dato-DXd for advanced or metastatic NSCLC with actionable genomic alterations progressing on or after targeted therapy and platinum-based chemotherapy?
 - a. No patients experienced a partial response across all actionable genomic alterations
 - b. Only patients with an EGFR mutation experienced tumor responses
 - c. Responses were seen across all actionable genomic alterations**